4 CHAPTER 4 92 43. Piyanova A, Lomazzo E, Bindila L, et al. Agerelated changes in the endocannabinoid system in the mouse hippocampus. Mech Ageing Dev. 2015;150:55-64. 44. Wagner EJ. Sex differences in cannabinoidregulated biology: A focus on energy homeostasis. Front Neuroendocrinol. 2016;40:101-109. 45. Craft RM, Marusich JA, Wiley JL. Sex differences in cannabinoid pharmacology: a reflection of differences in the endocannabinoid system? Life Sci. 2013;92(8-9):476-481. 46. Hirvonen J, Zanotti-Fregonara P, Gorelick DA, et al. Decreased Cannabinoid CB1 Receptors in Male Tobacco Smokers Examined With Positron Emission Tomography. Biol Psychiatry. 2018;84(10):715-721. 47. Kranaster L, Hoyer C, Aksay SS, et al. Electroconvulsive therapy enhances endocannabinoids in the cerebrospinal fluid of patients with major depression: a preliminary prospective study. Eur Arch Psychiatry Clin Neurosci. 2017;267(8):781-786. 48. Hill MN, Miller GE, Carrier EJ, Gorzalka BB, Hillard CJ. Circulating endocannabinoids and N-acyl ethanolamines are differentially regulated in major depression and following exposure to social stress. Psychoneuroendocrinology. 2009;34(8):12571262. 49. Patel S, Hillard CJ. Role of endocannabinoid signaling in anxiety and depression. Curr Top Behav Neurosci. 2009;1:347-371. 50. Jesulola E,Micalos P,Baguley IJ.Understanding the pathophysiology of depression: From monoamines to the neurogenesis hypothesis model - are we there yet? Behav Brain Res. 2018;341:79-90.
RkJQdWJsaXNoZXIy MTk4NDMw